Skip to main content
SpringerLink
Log in

The new selective IKs–blocking agent HMR 1556 restores sinus rhythm and prevents heart failure in pigs with persistent atrial fibrillation

  • ORIGINAL CONTRIBUTION
  • Published:
Basic Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Antiarrhythmic drugs for treatment of atrial fibrillation in patients with heart failure are limited by proarrhythmia and low efficacy. Experimental studies indicate that the pure IKs blocking agents chromanol 293b and HMR 1556 prolong repolarization more markedly at fast than at slow heart rates and during β–adrenergic stimulation. These properties may overcome some of the above quoted limitations.

Methods and results

Ten domestic swine underwent pacemaker implantation (PM) and atrial burst pacing to induce persistent AF. Four days after onset of persistent AF, pigs were randomized to HMR 1556 (30 mg/kg, p.o., 10 days) or placebo. All animals receiving HMR 1556 converted to SR (5.2 ± 1.9 days), whereas placebo pigs remained in AF. Pigs treated with placebo developed high ventricular rates (297 ± 5 bpm) and severe heart failure, whereas pigs treated with HMR 1556 remained hemodynamically stable. Left ventricular ejection fraction on the day of euthanization was significantly lower in the placebo compared to the HMR 1556 group (30 ± 4% vs. 69 ± 5%, p < 0.005). Similar results were seen with epinephrine levels (placebo 1563 ± 193 pmol/l vs. HMR 613 ± 196 pmol/l, p < 0.05). Right atrial monophasic action potentials were significantly longer in the HMR 1556 compared to the placebo group (230 ± 7 ms vs. 174 ± 13 ms, p < 0.05).

Conclusions

The new IKs blocker HMR 1556 efficiently and safely restores SR and prevents CHF in a model of persistent AF. Restoration of SR is most likely linked to a marked prolongation of atrial repolarization even at high heart rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bauer A, Becker R, Freigang KD, Senges JC, Voss F, Hansen A, Muller M, Lang HJ, Gerlach U, Busch A, Kraft P, Kubler W, Schols W (1999) Rate- and site-dependent effects of propafenone, dofetilide, and the new I(Ks)-blocking agent chromanol 293b on individual muscle layers of the intact canine heart. Circulation 100:2184–2190

    Google Scholar 

  2. Bauer A, Becker R, Freigang KD, Senges JC, Voss F, Kraft P, Kuebler W, Schoels W (2000) Electrophysiologic effects of the new I(Ks)-blocking agent chromanol 293b in the postinfarction canine heart. Preserved positive use-dependence and preferential prolongation of refractoriness in the infarct zone. Basic Res Cardiol 95:324–332

    Google Scholar 

  3. Bauer A, McDonald AD, Donahue JK (2004) Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 61:764–770

    Google Scholar 

  4. Bosch RF, Schneck AC, Csillag S, Eigenberger B, Gerlach U, Brendel J, Lang HJ, Mewis C, Gögelein H, Seipel L, Kühlkamp V (2003) Effects of the chromanol HMR 1556 on potassium currents in atrial myocytes. Naunyn Schmiedeberg’s Arch Pharamacol 367:281–288

    Google Scholar 

  5. Bosch RF, Gaspo R, Busch AE, Lang HJ, Li GR, Nattel S (1998) Effects of chromanol 293b, a selective blocker of the slow component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res 38:441–450

    Google Scholar 

  6. Brendorp B, Pedersen O, Torp-Pedersen C, Sahebzadah N, Kober L (2002) A benefit- risk assessment of class III antiarrhythmic agents. Drug Saf 25 (12):847–865

    Google Scholar 

  7. Castro A, Bianconi L, Santini M (2002) New antiarrhythmic drugs for the treatment of atrial fibrillation. Pacing Clin Electrophysiol 25:249–259

    Google Scholar 

  8. Franz MR, Burkhoff D, Spurgeon H, Weisfeldt ML, Lakatta EG (1986) In vitro validation of a new cardiac catheter technique for recording monophasic action potentials. Eur Heart J 7:34–41

    Google Scholar 

  9. Franz MR, Costard A (1988) Frequencydependent effects of quinidine on the relationship between action potential duration and refractoriness in the canine heart in situ. Circulation 77:1177–1184

    Google Scholar 

  10. Gerlach U, Brendel J, Lang HJ, Paulus EF, Weidmann K, Brüggemann A, Busch AE, Suessbrich H, Bleich M, Greger R (2001) Synthesis and activity of novel and selective IKS-channel blockers. J Med Chem 44:3831–3837

    Google Scholar 

  11. Han W, Wang Z, Nattel S (2001) Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. Am J Physiol Heart Circ Physiol 280:H1075–H1080

    Google Scholar 

  12. Haverkamp W, Shenasa M, Borggrefe M, Breithardt G (1995) Torsade de pointes. In: Zipes DP, Jalife J (eds) Cardiac Electrophysiology: From cell to bedside. Saunders: Philadelphia, pp 885–899

  13. Hohnloser SH (1997) Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management. Am J Cardiol 80:82–9G

    Google Scholar 

  14. Jurkiewicz NK, Sanguinetti MC (1993) Rate dependent prolongation of cardiac action potentials by a methanosulfonilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 72:75–83

    Google Scholar 

  15. Kettunen E, Parikka H, Verkkala K, Toivonen L (2004) Atrial refractoriness and action potential duration after sudden reversal of atrioventricular sequence. Pacing Clin Electrophysiol 27:10–18

    Google Scholar 

  16. Kowey PR, Yan GX, Dimino TL, Kocovic DZ (2003) Overview of the management of atrial fibrillation: what is the current state of the art? J Cardiovasc Electrophysiol 14:S275–S280

    Google Scholar 

  17. Lengyel C, Iost N, Virag L, Varro A, Lathrop DA, Papp JG (2001) Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br J Pharmacol 132:101–110

    Google Scholar 

  18. Li GR, Sun H, To J, Tse HF, Lau CP (2004) Demonstration of calcium-activated transient outward chloride current and delayed rectifier potassium currents in swine atrial myocytes. J Mol Cell Cardiol 36:495–504

    Google Scholar 

  19. Nakashima H, Gerlach U, Schmidt D, Nattel S (2004) In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc Res 61:705–714

    Google Scholar 

  20. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ (1988) Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 62:395–410

    Google Scholar 

  21. Roden DM (1996) Antiarrhythmic drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) The pharmacological basis of therapeutics. McGraw-Hill: New York, pp 839–874

  22. Sanguinetti MC, Jurkiewicz NK (1990) Two components of cardiac delayed rectifier K+ current. J Gen Physiol 96:195–215

    Google Scholar 

  23. Schiller N, Shah P, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2:358–367

    Google Scholar 

  24. Schram G, Pourrier M, Melnyk P, Nattel S (2002) Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res 90:939–950

    Google Scholar 

  25. Schreieck J, Wang Y, Gjini V Korth M, Zrenner B, Schomig A, Schmitt C (1997) Differential effect of _-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293b. J Cardiovasc Electrophysiol 8:1420–1430

    Google Scholar 

  26. Smeets JL, Allessie MA, Lammers WJ, Bonke FI, Hollen J (1986) The wavelength of the cardiac impulse and reentrant arrhythmias in isolated rabbit atrium. The role of heart rate, autonomic transmitters, temperature, and potassium. Circ Res 58:96–108

    Google Scholar 

  27. Szili-Torok T, Kimman GP, Theuns D, Poldermans D, Roelandt JR, Jordaens LJ (2002) Deterioration of left ventricular function following atrio-ventricular node ablation and right ventricular apical pacing in patients with permanent atrial fibrillation. Europace 4:61–65

    Google Scholar 

  28. Thomas GP, Gerlach U, Antzelevitch C (2003) HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol 41:140–147

    Google Scholar 

  29. Varro A, Balati B, Iost N, Takacs J, Virag L, Lathrop DA, Csaba L, Talosi L, Papp JG (2000) The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J Physiol 523:67–81

    Google Scholar 

  30. Volders PG, Stengl M, van Opstal JM, Gerlach U, Spatjens RL, Beekman JD, Sipido KR, Vos MA (2003) Probing the contribution of IKs to canine ventricular repolarization: key role for beta-adrenergic receptor stimulation. Circulation 107:2753–2760

    Google Scholar 

  31. Wijffels MC, Crijns HJ (2003) Recent advances in drug therapy for atrial fibrillation. J Cardiovasc Electrophysiol 14:S40–S47

    Google Scholar 

  32. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA (1995) Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92:1954–1968

    Google Scholar 

  33. Wirth KJ, Paehler T, Rosenstein B, Knobloch K, Maier T, Frenzel J, Brendel J, Busch AE, Bleich M (2003) Atrial effects of the novel K+-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc Res 60:298–306

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    A. Bauer, M. Koch,  P. Kraft,  R. Becker,  K. Kelemen, F. Voss, J. C. Senges,  H. A. Katus & W. Schoels

  2. DG Cardiovascular Diseases, Aventis Pharma, Frankfurt, Germany

    U. Gerlach

Authors
  1. A. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Kraft
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Kelemen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Voss
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. C. Senges
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. U. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. A. Katus
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W. Schoels
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Bauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bauer, ., Koch, M., Kraft, . et al. The new selective IKs–blocking agent HMR 1556 restores sinus rhythm and prevents heart failure in pigs with persistent atrial fibrillation. Basic Res Cardiol 100, 270–278 (2005). https://doi.org/10.1007/s00395-005-0522-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00395-005-0522-y

Key words

Search

Navigation